new molecules and indications for glp-1 medicines The expanding landscape of 對GLP-1#醫學醫療新的分子和突現性的適應症（New molecules and Emerging indications

The STEP 1 trial extension the largest semaglutide follow-up study found that participants regained roughly two-thirds of their prior weight loss within 52 weeks of stopping the drug

Take note: Protein alone wont preserve muscle

While new prescriptions of these medications for DMT2 increased 128%, it may be of more interest that new prescriptions for obesity grew 352% during this time

Bessette also said that more real-world evidence is needed to study the safety and effectiveness of GLP-1[s] and GLP-1/[gastric inhibitory polypeptides] in these underrepresented and previously excluded populations to guide treatment decisions.

Providers adjust based on your progress, side effects, and evolving needs

If your primary care provider has prescribed weight loss medication, dont leave anything to chance